amcure
Leopoldshafen
About amcure
amcure is a privately held, clinical-stage company developing peptide-based compounds for the treatment of highly metastatic forms of squamous cancer. Established in 2012, amcure GmbH is a spin-off from the Karlsruhe Institute of Technology (KIT) and is supported by a grant from the German Federal Ministry of Education and Research. amcure leverages its in-depth knowledge of CD44 target biology to develop a novel therapeutic approach to treat metastatic squamous tumors. In cancer, blocking the extracellular target CD44v6 has a beneficial effect on several relevant receptor tyrosine kinase pathways. Their first-in-class CD44v6-inhibitor AMC303 entered clinical development in solid tumors in Q4 2016.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $15.1M
- Funding stage: Early Stage Venture
- Last round: Grant (Aug 2017)
- Website: amcure.com
- Phone: 49 7247 934249-0
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/amcure-119553 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.